TY - JOUR
T1 - Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1
AU - Hunt, Joshua S.
AU - Romanelli, Frank
PY - 2009/3
Y1 - 2009/3
N2 - Inhibition of the human immunodeficiency virus type 1 (HIV-1) coreceptor is an encouraging new approach to pharmacotherapy against HIV. The HIV-1 strain makes use of either the CCR5 or the CXCR4 coreceptor to gain access into host CD4 + cells. Maraviroc, the first HIV-1 CCR5 coreceptor antagonist, blocks entry of HIV-1. This recently approved drug has demonstrated clinically significant decreases in plasma concentrations of HIV-1 RNA and increases in CD4 + cell counts; however, it is indicated only for use as salvage therapy. Drug resistance is a concern, as is selective pressure on viral coreceptor use, because viral coreceptor targets may switch as disease progresses. In addition, before maraviroc therapy can be started, costly assays are required to determine the host's viral coreceptor tropism. Emerging therapies targeting CXCR4, the other HIV coreceptor, have shown promise in decreasing plasma concentrations of HIV-1 RNA. Long-term studies with both targets are required to explore the critical issues of efficacy and immunologic safety, as the function of these coreceptors is linked to host chemokine pathways.
AB - Inhibition of the human immunodeficiency virus type 1 (HIV-1) coreceptor is an encouraging new approach to pharmacotherapy against HIV. The HIV-1 strain makes use of either the CCR5 or the CXCR4 coreceptor to gain access into host CD4 + cells. Maraviroc, the first HIV-1 CCR5 coreceptor antagonist, blocks entry of HIV-1. This recently approved drug has demonstrated clinically significant decreases in plasma concentrations of HIV-1 RNA and increases in CD4 + cell counts; however, it is indicated only for use as salvage therapy. Drug resistance is a concern, as is selective pressure on viral coreceptor use, because viral coreceptor targets may switch as disease progresses. In addition, before maraviroc therapy can be started, costly assays are required to determine the host's viral coreceptor tropism. Emerging therapies targeting CXCR4, the other HIV coreceptor, have shown promise in decreasing plasma concentrations of HIV-1 RNA. Long-term studies with both targets are required to explore the critical issues of efficacy and immunologic safety, as the function of these coreceptors is linked to host chemokine pathways.
KW - AIDS
KW - Acquired immunodeficiency syndrome
KW - Coreceptor antagonism
KW - Coreceptors
KW - HIV
KW - Human immunodeficiency virus
KW - Maraviroc
UR - http://www.scopus.com/inward/record.url?scp=62549162552&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=62549162552&partnerID=8YFLogxK
U2 - 10.1592/phco.29.3.295
DO - 10.1592/phco.29.3.295
M3 - Review article
C2 - 19249948
AN - SCOPUS:62549162552
SN - 0277-0008
VL - 29
SP - 295
EP - 304
JO - Pharmacotherapy
JF - Pharmacotherapy
IS - 3
ER -